Search details
1.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36895158
2.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36541152
3.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Article
in English
| MEDLINE | ID: mdl-32438407
4.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32731259
5.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33428632
6.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Article
in English
| MEDLINE | ID: mdl-32656799
7.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Article
in English
| MEDLINE | ID: mdl-33910333
8.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Article
in English
| MEDLINE | ID: mdl-32499244
9.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Article
in English
| MEDLINE | ID: mdl-30373884
10.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Article
in English
| MEDLINE | ID: mdl-30181174
11.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30559051
12.
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 25(3): e89-e97, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30408566
13.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Haematologica
; 104(7): 1440-1450, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30733268
14.
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Br J Haematol
; 182(6): 816-829, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29984830
15.
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Future Oncol
; 14(22): 2229-2237, 2018 Sep.
Article
in English
| MEDLINE | ID: mdl-29869556
16.
Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
BMC Nephrol
; 19(1): 178, 2018 07 13.
Article
in English
| MEDLINE | ID: mdl-30012107
17.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34636043
18.
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.
Blood
; 125(12): 1932-5, 2015 Mar 19.
Article
in English
| MEDLINE | ID: mdl-25645353
19.
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
Br J Haematol
; 175(1): 77-86, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27378193
20.
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.
Blood
; 124(8): 1296-9, 2014 Aug 21.
Article
in English
| MEDLINE | ID: mdl-24939658